We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PARP Inhibition in Epithelial Ovarian Cancer: High Hopes Undergo a Reality Check.
- Authors
Zorn, Kristin K.
- Abstract
The article discusses the reviews on the clinical trials using the poly(ADP-ribose) polymerase (PARP) inhibition in fallopian tube cancer (FTC) and primary peritoneal cancer (PTC). It mentions that the inhibition was inherent in homologous recombination in BRCA-deficient tumor through the alternative DNA repair pathway. It lists several identifiers that went through clinical trials which shows that the medication of 600 mg of olaparib twice daily increased the mononuclear cells into 90%. INSET: REFERENCE GUIDE.
- Subjects
ANTINEOPLASTIC agents; CLINICAL trials; ENZYME inhibitors; OVARIAN tumors; TRANSFERASES
- Publication
Oncology (08909091), 2012, Vol 26, Issue 2, p128
- ISSN
0890-9091
- Publication type
Article